- Home
- NEUP vs CMMB Comparison
NEUP vs CMMB Comparison
Compare NEUP & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUP
- CMMB
- Stock Information
- Founded
- NEUP 1996
- CMMB 2004
- Country
- NEUP United States
- CMMB Israel
- Employees
- NEUP N/A
- CMMB N/A
- Industry
- NEUP
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- NEUP
- CMMB Health Care
- Exchange
- NEUP Nasdaq
- CMMB Nasdaq
- Market Cap
- NEUP 12.7M
- CMMB 13.7M
- IPO Year
- NEUP N/A
- CMMB N/A
- Fundamental
- Price
- NEUP $17.24
- CMMB $3.38
- Analyst Decision
- NEUP Strong Buy
- CMMB Strong Buy
- Analyst Count
- NEUP 2
- CMMB 2
- Target Price
- NEUP $28.00
- CMMB $26.50
- AVG Volume (30 Days)
- NEUP 95.7K
- CMMB 263.1K
- Earning Date
- NEUP 11-15-2025
- CMMB 11-13-2025
- Dividend Yield
- NEUP N/A
- CMMB N/A
- EPS Growth
- NEUP N/A
- CMMB N/A
- EPS
- NEUP N/A
- CMMB N/A
- Revenue
- NEUP $15,649,448.00
- CMMB N/A
- Revenue This Year
- NEUP N/A
- CMMB N/A
- Revenue Next Year
- NEUP N/A
- CMMB N/A
- P/E Ratio
- NEUP N/A
- CMMB N/A
- Revenue Growth
- NEUP N/A
- CMMB N/A
- 52 Week Low
- NEUP $2.90
- CMMB $2.39
- 52 Week High
- NEUP $126.00
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- NEUP 60.56
- CMMB 63.47
- Support Level
- NEUP $14.64
- CMMB $3.03
- Resistance Level
- NEUP $19.21
- CMMB $3.55
- Average True Range (ATR)
- NEUP 2.14
- CMMB 0.22
- MACD
- NEUP -0.03
- CMMB 0.04
- Stochastic Oscillator
- NEUP 59.46
- CMMB 76.42
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.